Eton Pharmaceuticals (ETON) risk factors

53 risks, 7 new, 6 dropped, 2 reworded since the prior year. New disclosures detail growing risks from the Inflation Reduction Act, government price reporting, and supply chain tracking.

52 risks. Eton Pharmaceuticals faces substantial risks centered on rare disease drug development, regulatory approvals, and intellectual property protection. The company is vulnerable to patent litigation, third-party licensing dependencies, and compliance issues. Financial constraints and capital raising needs heavily influence its business viability.